Image Source: PR Newswire
Indegene Ltd (INEG.NS), a digital-first life sciences commercialization company, has entered into a strategic partnership with Datavant, a leader in real-world data linkage and privacy-preserving analytics, aiming to significantly enhance patient recruitment and data management for clinical trials. This alliance promises to transform clinical trial efficiency, speed up drug development, and ultimately improve patient outcomes globally.
Tackling the Clinical Trial Recruitment Challenge
Clinical trials, essential for bringing new drugs and therapies to market, often face delays due to difficulties in identifying and enrolling suitable patients. Indegene’s collaboration with Datavant addresses this bottleneck by combining advanced data science, AI-driven analytics, and privacy-preserving data tokenization technologies.
By linking disparate healthcare datasets such as electronic health records (EHR), claims data, pharmacy information, and lab results, the partnership enables a comprehensive understanding of patient journeys without compromising individual privacy. This capability facilitates precise patient identification, enabling targeted recruitment strategies that dramatically reduce trial timelines.
Data-Driven and Privacy-Centric Approach
Datavant’s patented tokenization technology allows for the anonymized linking of clinical data sets, ensuring compliance with stringent data privacy regulations worldwide. Indegene integrates these capabilities within its proprietary NEXT Clinical Trials platform, offering clients a unified approach to streamline trial design, recruitment, and monitoring.
Together, they provide pharmaceutical companies and contract research organizations (CROs) with actionable insights that optimize site activation, patient engagement, and retention—key factors for successful trial completion.
Shared Vision for Faster, Efficient Clinical Development
Ram Yeleswarapu, Senior Vice President of Enterprise Clinical Solutions at Indegene, highlighted the strategic alignment: “Our partnership with Datavant enables us to harness data and technology across the clinical trial value chain. We aim to deliver faster, more efficient, and cost-effective drug development.”
Arjun P. Gupta, Founder and CEO of Smart Joules, noted the transformative potential this creates for the life sciences ecosystem by enhancing patient-centric trial designs and facilitating regulatory and payer submissions with robust real-world evidence.
Industry Impact and Future Outlook
The combined efforts of Indegene and Datavant are set to redefine clinical trial operations by reducing the time-to-market for life-saving therapies and increasing inclusivity in clinical research by reaching diverse patient populations more effectively.
Innovations brought by this partnership also promise to lower clinical trial costs and risks while improving the overall quality and reliability of clinical data.
About Indegene
Indegene is a global healthcare solutions company that integrates healthcare expertise, analytics, digital technology, and agile operations to serve leading biopharmaceutical, biotech, and medical device companies worldwide. Its solutions span commercialization, medical affairs, and clinical development, focusing on delivering enhanced patient experiences and outcomes.
About Datavant
Datavant is a pioneer in privacy-preserving data linkage and real-world data solutions, enabling healthcare organizations to unlock insights from fragmented datasets securely. Its technology empowers pharmaceutical companies to make informed clinical and commercial decisions while maintaining patient confidentiality.
Sources: Yahoo Finance, TrialHub, Datavant, Indegene LinkedIn Announcement
Advertisement
Advertisement
